Defunct Company
Total Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
2,707
NCT02914301
Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study
Phase: N/A
Role: Collaborator
Start: Jul 31, 2015
Completion: May 31, 2016
NCT04048135
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jul 29, 2019
Completion: Jan 19, 2022
NCT04541186
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Phase: Phase 2
Start: Sep 1, 2020
Completion: May 31, 2022
NCT04929483
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
Start: Jun 4, 2021
Completion: Oct 8, 2024
NCT05022693
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
Phase: Phase 1
Start: Aug 16, 2021
Completion: Dec 21, 2021
NCT05852431
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Phase: Phase 3
Start: Jun 15, 2023
Completion: Apr 30, 2026
NCT06318169
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Start: Mar 13, 2024
Completion: Feb 28, 2029
NCT06419374
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Start: May 24, 2024
Completion: Aug 31, 2031